Aminocaproic Acid(a mee noe ka proe’ ik)
Amicar
PREGNANCY CATEGORY C
Drug class
Systemic hemostatic drug
Therapeutic Actions
Inhibits fibrinolysis by inhibiting plasminogen activator substances and by antiplasmin activity; this action prevents the breakdown of clots.
Indications
Treatment of excessive bleeding resulting from systemic hyperfibrinolysis and urinary fibrinolysis
Unlabeled uses: Prevention of recurrence of subarachnoid hemorrhage; management of amegakaryocytic thrombocytopenia; to decrease the need for platelet administration; to abort and treat attacks of hereditary angioneurotic edema; to reduce postoperative bleeding complications in cardiac and orthopedic procedures; acute promyelocytic leukemia with coagulopathy associated with low levels of alpha-2-plasmin inhibitor
Contraindications and Cautions
Contraindicated with allergy to aminocaproic acid, active intravascular clotting, cardiac disease, renal impairment, hematuria of upper urinary tract origin, hepatic impairment, lactation.
Use cautiously with hyperfibrinolysis, pregnancy.
Available Forms
Tablets—500, 1,000 mg; injection—250 mg/mL; oral solution—250 mg/mL
Dosages
Adults
Treatment of excessive bleeding: Initial dose of 5 g PO or IV followed by 1–1.25 g every hr to produce and sustain plasma levels of 0.13 mg/mL; do not administer more than 30 g in 24 hr.
Acute bleeding: 4–5 g IV in 250 mL of diluent during the first hour of infusion; then continuous infusion of 1 g/hr in 50 mL of diluent. Continue for 8 hr or until bleeding stops.
Prevention of recurrence of subarachnoid hemorrhage: 36 g/day in six divided doses, PO or IV.
Pediatric patients
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
